# Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye

> **NCT01143402** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 120 (actual)

## Conditions studied

- Iris Melanoma
- Medium/Large Size Posterior Uveal Melanoma
- Ocular Melanoma With Extraocular Extension
- Recurrent Uveal Melanoma
- Small Size Posterior Uveal Melanoma
- Stage IV Uveal Melanoma

## Interventions

- **DRUG:** Dacarbazine
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Quality-of-Life Assessment
- **DRUG:** Selumetinib
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT01143402
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2017-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01143402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01143402, "Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01143402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*